Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A

Affiliations

• ¹ Department of Medicine, Hematology-Oncology Section, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
• ² Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
• ³ Algemeen Ziekenhuis Sint Jan, Brugge-Oostende, Belgium.
• ⁴ Ruijin Hospital, Shanghai, China.
• ⁵ Aichi Cancer Center, Chikusa-ku, Nagoya, Japan.
• ⁶ Norton Cancer Institute, Louisville, Kentucky, USA.
• ⁷ Department of Medical Imaging, Haematology, and Oncology, University of São Paulo at Ribeirão Preto Medical School, Sao Paulo, Brazil.
• ⁸ Hematology, Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy.
• ⁹ University Hospital Brno and Masaryk University, Brno, Czech Republic.
• ¹⁰ Genentech, Inc, South San Francisco, California, USA.
• ¹¹ AbbVie, Inc, North Chicago, Illinois, USA.
• ¹² Department of Internal Medicine, Division of Hematology and Oncology, University of California Davis School of Medicine, Sacramento, California, USA.